We focus on the discovery and development of novel therapeutic proteins through different collaboration frameworks.
Our mission is to vastly accelerate the process of therapeutic protein discovery, by designing radically novel molecules to achieve specific and potent pharmacological activity.
Our core technologies are based on a set of computational design algorithms, that enables us to create guided molecular interactions and build architectures at atomic precision.
We experimentally characterise our designs' biophysical properties, atomic structure, and pharmacological activity in an expedited pipeline, allowing fast arrival at preclinical candidates.
Fragment-based protein design of molecules with novel folds and sequences to predetermined backbone architectures.
Bespoke design of single-domain, high affinity binders directed against defined conformational epitopes on target proteins of interest.
Topological rewiring of existing proteins through de novo loop design to simplify the underlying folds; enhancing their biophysical properties.
Please send us your questions or request an appointment.
Registered address: Heliopolis Biotechnology US, LLC, 1209 Orange Street, Wilmington, Delaware 19801 USA Correspondence address: Heliopolis Biotechnology US, LLC, 85 Uinta Way, Suite 901, Denver, Colorado 80230 USA